



Technology Pipeline

CELL & GENE THERAPY



Anschutz

Innovations



Advancing to the Clinic

The Gates Institute is partnering with CU Anschutz researchers to de-risk and translate these groundbreaking cell and gene therapies from development into Phase 1 first-in-human clinical trials.

PRINCIPAL INVESTIGATOR (PI)

Principal Investigator (PI)	Project ID	Project Name	Status	Category
Balaji Sridhar	4987	INJECTABLE HYDROGEL THERAPY FOR OSTEOARTHRITIS	AVAILABLE	Platform Tech
Holger Russ	4898	HUMAN THYMIC EPITHELIAL CELL THERAPY	PARTNERED	Regenerative Medicine
Holger Russ	5178	CELL THERAPY FOR T1D	AVAILABLE	Regenerative Medicine
Igor Kogut	5077	CELLULAR REJUVENATION	AVAILABLE	Regenerative Medicine
Kunhua Song	4946	GENE THERAPY FOR DANON DISEASE	AVAILABLE	New Target
Maria Canto-Soler	4705	RETINAL TRANSPLANT FOR AMD	AVAILABLE	Regenerative Medicine
Mark Kohler	5685	CAR CONSTRUCT WITH LAT FOR LOW ANTIGEN CANCERS	AVAILABLE	Platform Tech
Mark Kohler	5694	CAR CONSTRUCT WITH CD3E FOR LOW ANTIGEN CANCERS	AVAILABLE	Platform Tech
Mayumi Fujita	5974	ENGINEERED TREGS FOR T1D	AVAILABLE	Regenerative Medicine
Mingxia Huang	4892	THERAPEUTICALLY TARGETING CTBP IN MILD TBI	AVAILABLE	New Target
Terry Fry	5905	BAIT CAR FOR AUTOIMMUNE DISEASE	AVAILABLE	Regenerative Medicine



About our partners

GATES INSTITUTE

Gates Institute is a world-class translational research institute with cell/gene and biologics cGMP manufacturing capabilities. Based at the University of Colorado Anschutz, it is part of a rich biomedical ecosystem, enabling the translation of life saving treatments for a host of adult and pediatric diseases at unmatched speed and scope. They bring together and support researchers and clinicians who specialize in regenerative, cell/gene, and biologics therapies, accelerating discoveries from concept to cures.

The state-of-the-art Gates Biomanufacturing Facility is an FDA-compliant cGMP facility with 21,000 square feet of manufacturing, laboratory, warehouse, and administrative space. Its unique positioning within the Fitzsimons Innovation Community enables partnerships with both campus researchers and industry biotechnology companies. The facility excels to facilitate process development, scale up, and GMP manufacture for human use, materials management, product quality control, and IND submissions.


In addition, Gates Institute is committed to continuing to grow the cell therapy ecosystem at CU Anschutz. To date, the Gates Grubstake Fund has supported over 29 research projects with nearly \$10MM in funding.

For more information, visit www.gates.cuanschutz.edu and www.gatesbiomanufacturing.com



 *New Target*  *Platform Tech*  *Regenerative Medicine*

 **AVAILABLE**  **PARTNERED**



Cardiology

Jeff Jacot

4290

PATCH FOR CONGENITAL HEART DEFECTS



Dermatology

Igor Kogut

3555

IPSC REPROGRAMMING & GENE-CORRECTION FOR EPIDERMOLYSIS BULLOSA



Yiqun Shellman

4999

BLC2 INHIBITOR TREATS MELANOMA



Endocrine/Metabolism

Holger Russ

5898

CELL THERAPY FOR T1D



Holger Russ

6002

TAILORABLE NANOPARTICLES FOR BETA CELLS



PRINCIPAL INVESTIGATOR (PI)



Immunology

Principal Investigator (PI)	Count	Project Title	Category
Jordan Jacobelli	5985	ENGINEERING CELLS TO MIGRATE INTO SOLID TUMORS	Platform Tech
Kole DeGolier	6335	RUNX2 MODULATION ENHANCES T CELL THERAPIES	Platform Tech
Michael Verneris	5426	INNATE LYMPHOID CELL THERAPY	Regenerative Medicine
Michael Verneris	5507	INNATE LYMPHOID CELL THERAPY	Regenerative Medicine
Terry Fry	5004	MULTIVALENT CARS (FLT3, CD19, CD22, CD33)	New Target

Pediatrics

Sujatha Venkataraman	6129	CD99 CAR FOR FATAL PEDIATRIC BRAIN TUMORS	New Target
Sujatha Venkataraman	6133	LOGIC-GATED CAR-T FOR BRAIN TUMORS	New Target

PRINCIPAL INVESTIGATOR (PI)



Where we are located

CU ANSCHUTZ MEDICAL CAMPUS

The University of Colorado Anschutz is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UHealth University of Colorado Hospital and Children's Hospital Colorado - that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, the CU Anschutz delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by over \$704 million in research grants.

For more information, visit www.cuanschutz.edu.













 *New Target*
 *Platform Tech*
 *Regenerative Medicine*


 AVAILABLE
 PARTNERED



Oncology/Hematology

PRINCIPAL INVESTIGATOR (PI)

Aaron Johnson	5612	RNA HOTAIR FOR CANCER	
Eduardo Davila	5493	UNIVERSAL TCR	
Holger Russ	5287	PERSONALIZED THYMIC CELL THERAPY	
Jill Slansky	5921	GRANZYME MODULATION FOR CARS	
Mark Kohler	6343	CD64 CAR for R/R AML	
Mercedes Rincon	6378	INCREASING RESPIRATION IN CAR-T CELLS	
Michael Verneris	5508	HOMING OF B7H3 CAR THERAPY FOR SOLID TUMORS	
Rajeev Vibhakar	0082	HOMING OF B7H3 CAR THERAPY	
Terry Fry	25004	TARGETING FLT3 IN AML	
Terry Fry	6031	HUMAN ANTIBODY VH DOMAINS TO FLT3	



About us

CU ANSCHUTZ INNOVATIONS

We bring together industry partners, entrepreneurs, and investors to help CU Researchers create biomedical technology that improves the quality of life worldwide. With expertise in patents, copyrights, and licensing, CU Anschutz Innovations translates discovery into impact through transparent, flexible, best practice intellectual property management services.

Located on University of Colorado Anschutz Medical Campus, Innovations provides access to an extensive portfolio of biomedical technologies, clinical validation opportunities, and resources for startup development.

Let's start a conversation.



CONTACT

Doreen Molik, MS
Senior Licensing Manager
CU Anschutz Innovations
University of Colorado Anschutz Medical Campus
doreen.molik@cuanschutz.edu





Anschutz

Innovations

Anschutz Health Sciences Building
1890 N. Revere Ct., Suite 6202
Aurora, CO 80045

(303) 724-3720
innovations@cuanschutz.edu

 [cuanschutz-innovations/](#)

 [@cuanschutz-innovations](#)



WEBSITE Scan to view our website and to learn more about how we can best support you >

cuanschutz.edu/innovations

